Evidence map›Paper›PMID 36708563›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2023

ADAM10 Gene Polymorphism and Its Relationship to Hepatocellular Carcinoma in Egyptian HCV Patients Receiving Direct-Acting Antiviral Therapies (DAAs).

Samar Ghanem, Gamalat El Gedawy, Sania Yehia, Hanan Bedair, Samah Awad, Wael Abdel-Razek, Mostafa Elhelbawy, Dalia El-Sabaawy, Ashraf Yousif Elfert

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Samar GhanemDepartment of Clinical Biochemistry and Molecular Diagnostics, National Liver Institute, Menoufia University, Egypt.
Gamalat El GedawyDepartment of Clinical Biochemistry and Molecular Diagnostics, National Liver Institute, Menoufia University, Egypt.
Sania YehiaDepartment of Epidemiology and Preventive Medicine, National Liver Institute, Menoufia University, Egypt.
Hanan BedairDepartment of Clinical Pathology, National Liver Institute, Menoufia University, Egypt.
Samah AwadDepartment of Clinical Microbiology and Immunology Department, National Liver Institute, Menoufia University, Egypt.
Wael Abdel-RazekDepartment of Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Egypt.
Mostafa ElhelbawyDepartment of Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Egypt.
Dalia El-SabaawyDepartment of Clinical Pharmacy, Pharmacy Collage, Menoufia University, Egypt.
Ashraf Yousif ElfertDepartment of Clinical Biochemistry and Molecular Diagnostics, National Liver Institute, Menoufia University, Egypt.
Menoufia University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe aim of this study was to investigate the ADAM 10 rs.653765 SNP genetic polymorphism in the hepatocellular carcinoma occurrence (de novo and post DAAs).

methodsThis study was conducted on 360 participants divided to 4 groups. Group 1: 90 chronic adult patients infected with HCV received DAAs regimens and evolved HCC during the period of follow up. Group 2: Another 90 HCV patients received the same DAAs regimens and did not show HCC manifestations during the same follow up period. Group 3 included 90 de novo HCC patients (did not receive any DAAs). Finally, 90 apparently healthy participants as group 4. Clinical and laboratory data were evaluated, and ADAM 10 genotyping were performed using qPCR.

resultsThe study showed statistically significant between HCC de novo and HCC deterioration on top of DAAs according to three scoring systems (Child Pugh, BCLC and HKLC) with p- value <0.05. Regarding ADAM10 gene polymorphism, the study showed a significant difference between CC versus CT+TT genotypes of HCC groups according to Child Bugh, BCLC and HKLC staging systems. Yet, no significant difference was found when ADAM10 genotypes and allele frequencies were compared between the four different studied groups. No difference in the survival rate between HCC de novo and on the top of DAAs but more aggressive stages with HCC on top of DAAs.

conclusionADAM10 genotypes did not show any significant association with HCC. Also, no differences in the death rate recorded between the de novo HCC and HCC post DAAs treatment with statistical significant worse staging of HCC post DAAs and were noted. the study showed a significant difference between CC versus CT+TT genotypes of HCC groups according to Child Bugh, BCLC and HKLC staging systems.<br />.

Indexed as

Carcinoma, HepatocellularHepatitis C, ChronicLiver NeoplasmsADAM10 ProteinAdultAmyloid Precursor Protein SecretasesAntiviral AgentsEgyptHepacivirusHumansMembrane ProteinsPolymorphism, GeneticADAM10 ProteinADAM10 protein, humanAmyloid Precursor Protein SecretasesAntiviral AgentsMembrane ProteinsHCCHCVLiver

Identifiers

PMID36708563
PMCPMC10152868
OpenAlexW4318387624

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.